IV NK cell treatment for advanced cancers that returned
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old
- Your cancer is an advanced solid tumor, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma
- You have at least one spot doctors can measure or track on scans or exams
- You are well enough to do daily activities most of the time (performance status 0 or 1)
- Your blood counts and kidney/liver tests are within acceptable limits
- You have been told about the study and agree to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational natural killer (NK) cell therapy for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these immune cells can shrink tumors and are safe.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
This early-stage trial tests a new type of immune cell therapy (NK cells boosted with a protein called IL-15) to treat solid cancers that have spread or come back after standard treatment. The goal is to see if this approach can help shrink tumors and improve survival.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.